Gland Pharma, 543245, GLAND Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

31,847.42
41.35
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

29,560.42
0.93%
3.40

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

11.81
10.16
15.72

EBITDA CAGR (%)

10 Years
5 Years
3 Years

11.13
-0.52
4.37

PAT CAGR (%)

10 Years
5 Years
3 Years

13.26
-6.87
-3.65

P:E (Median)

8 Years
5 Years
3 Years

-
-
37.36

P:BV (Average)

8 Years
5 Years
3 Years

-
-
3.32

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
17.70

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 46.9 42.4 57.39 70.37
P/E Ratio 41.25 45.63 33.71 27.49
Revenue 5642 5617 6360 7071
EBITDA 1333 1529 1887
Net Income 772 699 938 1147
ROA 8 8.5 9.6
P/B Ratio 3.54 3.17 2.91
ROE 9.26 9.82 10.82
FCFF 718 363 792
FCFF Yield 3.03 1.53 3.35
Net Debt -1467 -2630 -3228
BVPS 546.13 611 665

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 1,038.84 1,012.02 2.65% 1,030.35 1,174.83 -12.30% 1,010.78 1,097.86 -7.93% 1,062.99 1,010.67 5.18%
Expenses 679.99 718.47 -5.36% 636.23 742.00 -14.25% 619.64 728.37 -14.93% 699.19 663.57 5.37%
EBITDA 358.85 293.55 22.24% 394.12 432.83 -8.94% 391.14 369.49 5.86% 363.80 347.10 4.81%
EBIDTM 34.54% 29.01% 38.25% 36.84% 38.70% 33.66% 34.22% 34.34%
Other Income 54.74 48.49 12.89% 43.72 46.95 -6.88% 65.06 43.39 49.94% 57.80 41.11 40.60%
Interest 7.43 0.91 716.48% 3.45 4.53 -23.84% 18.31 0.80 2,188.75% 0.17 0.91 -81.32%
Depreciation 43.77 40.82 7.23% 43.07 42.56 1.20% 43.77 40.33 8.53% 41.61 40.24 3.40%
PBT 362.38 300.31 20.67% 391.32 432.69 -9.56% 394.13 371.75 6.02% 379.82 347.06 9.44%
Tax 93.13 77.39 20.34% 101.32 111.28 -8.95% 99.01 94.95 4.28% 98.11 89.54 9.57%
PAT 269.26 222.92 20.79% 290.00 321.41 -9.77% 295.12 276.81 6.61% 281.71 257.53 9.39%
PATM 25.92% 22.03% 28.15% 27.36% 29.20% 25.21% 26.50% 25.48%
EPS 16.34 13.53 20.77% 17.60 19.50 -9.74% 17.91 16.80 6.61% 17.09 15.63 9.34%

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 1,505.62 1,401.71 7.41% 1,424.91 1,537.45 -7.32% 1,384.05 1,545.15 -10.43% 1,405.83 1,373.42 2.36%
Expenses 1,137.86 1,137.31 0.05% 1,077.39 1,178.80 -8.60% 1,024.10 1,188.76 -13.85% 1,108.78 1,049.35 5.66%
EBITDA 367.76 264.40 39.09% 347.52 358.65 -3.10% 359.96 356.39 1.00% 297.06 324.08 -8.34%
EBIDTM 24.43% 18.86% 24.39% 23.33% 26.01% 23.07% 21.13% 23.60%
Other Income 57.53 51.43 11.86% 44.03 42.15 4.46% 58.49 37.39 56.43% 59.66 53.15 12.25%
Interest 11.50 5.62 104.63% 7.45 9.96 -25.20% 22.82 5.28 332.20% 6.11 6.05 0.99%
Depreciation 101.05 91.96 9.88% 95.76 92.61 3.40% 96.33 105.34 -8.55% 93.83 81.30 15.41%
PBT 312.74 218.24 43.30% 288.33 298.23 -3.32% 299.30 283.16 5.70% 256.78 289.89 -11.42%
Tax 97.26 74.48 30.59% 101.79 105.81 -3.80% 94.61 91.30 3.63% 93.25 95.81 -2.67%
PAT 215.48 143.76 49.89% 186.54 192.42 -3.06% 204.69 191.86 6.69% 163.53 194.08 -15.74%
PATM 14.31% 10.26% 13.09% 12.52% 14.79% 12.42% 11.63% 14.13%
EPS 13.08 8.73 49.83% 11.32 11.68 -3.08% 12.42 11.65 6.61% 9.93 11.78 -15.70%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 4,142.96 4,116.15 4,167.43 3,616.53 4,400.71 3,462.88 2,633.24 2,044.20 1,619.94 1,479.18 1,347.87 Net Sales Growth -3.55% -1.23% 15.23% -17.82% 27.08% 31.51% 28.82% 26.19% 9.52% 9.74% Cost Of Goods Sold 1,678.56 1,730.60 1,820.31 1,685.42 2,109.22 1,219.00 836.07 626.35 479.75 375.07 540.21 Gross Profit 2,464.40 2,385.55 2,347.12 1,931.10 2,291.49 2,243.88 1,797.18 1,417.85 1,140.18 1,104.11 807.66 GP Margin 59.48% 57.96% 56.32% 53.40% 52.07% 64.80% 68.25% 69.36% 70.38% 74.64% 59.92% Total Expenditure 2,635.05 2,673.53 2,758.65 2,597.98 2,890.07 2,160.61 1,677.77 1,337.89 1,084.84 854.19 845.63 Power & Fuel Cost - 120.38 117.19 124.84 95.05 74.58 78.50 74.03 60.35 49.24 46.96 % Of Sales - 2.92% 2.81% 3.45% 2.16% 2.15% 2.98% 3.62% 3.73% 3.33% 3.48% Employee Cost - 439.02 409.94 399.70 338.57 311.36 277.66 222.95 179.08 153.42 131.30 % Of Sales - 10.67% 9.84% 11.05% 7.69% 8.99% 10.54% 10.91% 11.05% 10.37% 9.74% Manufacturing Exp. - 222.18 218.95 194.21 179.85 436.84 391.88 337.81 269.23 217.13 72.95 % Of Sales - 5.40% 5.25% 5.37% 4.09% 12.61% 14.88% 16.53% 16.62% 14.68% 5.41% General & Admin Exp. - 98.95 109.27 119.02 93.79 58.62 57.77 47.00 78.76 42.74 32.91 % Of Sales - 2.40% 2.62% 3.29% 2.13% 1.69% 2.19% 2.30% 4.86% 2.89% 2.44% Selling & Distn. Exp. - 23.31 34.66 30.26 40.98 36.69 17.08 13.88 9.93 11.40 15.80 % Of Sales - 0.57% 0.83% 0.84% 0.93% 1.06% 0.65% 0.68% 0.61% 0.77% 1.17% Miscellaneous Exp. - 39.10 48.31 44.53 32.61 23.51 18.82 15.86 7.73 5.19 15.80 % Of Sales - 0.95% 1.16% 1.23% 0.74% 0.68% 0.71% 0.78% 0.48% 0.35% 0.41% EBITDA 1,507.91 1,442.62 1,408.78 1,018.55 1,510.64 1,302.27 955.47 706.31 535.10 624.99 502.24 EBITDA Margin 36.40% 35.05% 33.80% 28.16% 34.33% 37.61% 36.28% 34.55% 33.03% 42.25% 37.26% Other Income 221.32 215.07 166.67 240.46 223.94 134.78 139.17 85.56 48.79 33.56 36.76 Interest 29.36 22.84 7.84 7.41 5.24 3.41 7.18 3.56 4.13 6.39 16.42 Depreciation 172.22 169.27 162.11 146.74 110.30 98.78 94.59 81.96 78.21 74.15 63.46 PBT 1,527.65 1,465.59 1,405.50 1,104.86 1,619.04 1,334.85 992.87 706.36 501.56 578.01 459.11 Tax 391.57 375.83 362.17 272.58 406.89 337.85 220.01 234.45 180.45 164.28 145.51 Tax Rate 25.63% 25.64% 25.77% 26.00% 25.13% 25.31% 22.16% 34.16% 35.98% 28.42% 31.69% PAT 1,136.09 1,089.75 1,043.33 775.83 1,212.15 997.00 772.86 451.91 321.11 413.73 313.61 PAT before Minority Interest 1,136.09 1,089.75 1,043.33 775.83 1,212.15 997.00 772.86 451.91 321.11 413.73 313.61 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 27.42% 26.47% 25.04% 21.45% 27.54% 28.79% 29.35% 22.11% 19.82% 27.97% 23.27% PAT Growth 5.32% 4.45% 34.48% -36.00% 21.58% 29.00% 71.02% 40.73% -22.39% 31.93% EPS 68.94 66.13 63.31 47.08 73.55 60.50 46.90 27.42 19.48 25.10 19.03

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Net Sales 5,720.41 5,616.50 5,664.72 3,624.60 4,400.71 3,462.88 2,633.24 Net Sales Growth -2.34% -0.85% 56.29% -17.64% 27.08% 31.51% Cost Of Goods Sold 2,047.25 2,090.38 2,173.09 1,685.42 2,109.11 1,219.00 836.07 Gross Profit 3,673.16 3,526.12 3,491.63 1,939.17 2,291.60 2,243.88 1,797.18 GP Margin 64.21% 62.78% 61.64% 53.50% 52.07% 64.80% 68.25% Total Expenditure 4,348.13 4,347.58 4,331.65 2,599.84 2,890.56 2,160.65 1,677.77 Power & Fuel Cost - 199.15 229.99 124.84 95.05 74.58 78.50 % Of Sales - 3.55% 4.06% 3.44% 2.16% 2.15% 2.98% Employee Cost - 1,401.56 1,256.89 403.26 338.57 311.36 277.66 % Of Sales - 24.95% 22.19% 11.13% 7.69% 8.99% 10.54% Manufacturing Exp. - 347.18 327.19 194.23 179.85 436.84 391.88 % Of Sales - 6.18% 5.78% 5.36% 4.09% 12.61% 14.88% General & Admin Exp. - 206.62 217.36 120.53 94.28 58.66 57.77 % Of Sales - 3.68% 3.84% 3.33% 2.14% 1.69% 2.19% Selling & Distn. Exp. - 27.48 37.46 27.03 40.98 36.69 17.08 % Of Sales - 0.49% 0.66% 0.75% 0.93% 1.06% 0.65% Miscellaneous Exp. - 75.20 89.66 44.53 32.72 23.51 18.82 % Of Sales - 1.34% 1.58% 1.23% 0.74% 0.68% 0.71% EBITDA 1,372.30 1,268.92 1,333.07 1,024.76 1,510.15 1,302.23 955.47 EBITDA Margin 23.99% 22.59% 23.53% 28.27% 34.32% 37.61% 36.28% Other Income 219.71 213.61 170.24 240.46 223.94 134.78 139.17 Interest 47.88 42.00 26.20 7.45 5.24 3.41 7.18 Depreciation 386.97 377.87 344.57 146.74 110.30 98.78 94.59 PBT 1,157.15 1,062.66 1,132.54 1,111.04 1,618.55 1,334.81 992.87 Tax 386.91 364.13 360.08 273.54 406.89 337.85 220.01 Tax Rate 33.44% 34.27% 31.79% 25.94% 25.14% 25.31% 22.16% PAT 770.24 698.53 772.46 781.04 1,211.66 996.96 772.86 PAT before Minority Interest 770.24 698.53 772.46 781.04 1,211.66 996.96 772.86 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 13.46% 12.44% 13.64% 21.55% 27.53% 28.79% 29.35% PAT Growth 6.66% -9.57% -1.10% -35.54% 21.54% 29.00% EPS 46.74 42.39 46.87 47.39 73.52 60.50 46.90

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 9,755.10 8,995.29 7,953.30 7,158.23 5,903.28 3,646.24 2,862.11 2,410.42 2,089.81 1,677.07 Share Capital 16.48 16.47 16.47 16.43 16.36 15.49 15.49 15.49 15.49 15.49 Total Reserves 9,738.57 8,977.43 7,935.16 7,128.56 5,861.51 3,614.26 2,846.62 2,394.93 2,074.32 1,661.57 Non-Current Liabilities 142.75 131.60 89.68 93.97 80.31 80.78 127.79 139.37 130.55 121.95 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50.17 Unsecured Loans 1.11 2.55 3.26 3.82 3.93 4.07 4.96 5.49 5.92 6.37 Long Term Provisions 22.84 20.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Liabilities 523.76 414.20 730.20 581.94 512.46 359.02 532.68 378.55 253.38 287.29 Trade Payables 385.87 281.19 589.42 462.76 396.28 249.09 446.20 292.42 189.29 88.51 Other Current Liabilities 88.03 100.94 109.46 76.42 62.36 81.73 72.60 71.13 61.87 151.77 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 39.90 Short Term Provisions 49.87 32.07 31.32 42.75 53.82 28.20 13.88 15.01 2.23 7.12 Total Liabilities 10,421.61 9,541.09 8,773.18 7,834.14 6,496.05 4,086.04 3,522.58 2,928.34 2,473.74 2,086.31 Net Block 1,744.99 1,693.73 1,570.55 1,502.19 954.23 968.10 928.74 842.64 871.58 787.88 Gross Block 2,798.04 2,579.91 2,294.95 2,081.32 1,430.70 1,347.81 1,219.58 1,054.45 1,005.52 1,020.22 Accumulated Depreciation 1,053.05 886.18 724.41 579.13 476.46 379.71 290.83 211.81 133.94 232.34 Non Current Assets 4,654.65 4,969.76 1,884.84 1,989.70 1,372.99 1,239.75 1,165.13 1,077.36 1,065.60 1,014.41 Capital Work in Progress 42.20 120.00 177.22 190.75 337.81 188.47 123.16 198.88 161.15 202.10 Non Current Investment 2,789.57 2,385.74 8.16 8.16 0.55 0.00 0.00 0.00 0.00 0.17 Long Term Loans & Adv. 77.89 114.38 128.92 286.40 77.97 81.52 111.89 33.89 29.42 21.63 Other Non Current Assets 0.00 655.91 0.00 2.21 2.43 1.66 1.33 1.95 3.44 2.62 Current Assets 5,766.96 4,571.32 6,888.34 5,844.44 5,123.07 2,846.29 2,357.46 1,850.98 1,408.15 1,071.90 Current Investments 0.00 0.00 0.00 154.87 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 1,254.23 1,260.21 1,945.30 1,185.67 1,275.17 756.28 911.88 512.83 378.72 367.08 Sundry Debtors 1,142.90 1,171.40 862.84 1,074.81 670.97 601.78 506.10 475.21 417.87 350.69 Cash & Bank 2,432.62 1,598.55 3,767.00 3,085.80 3,005.20 1,325.19 753.35 670.84 533.08 273.23 Other Current Assets 937.21 104.76 90.83 96.75 171.72 163.03 186.13 192.10 78.48 80.91 Short Term Loans & Adv. 810.85 436.41 222.37 246.55 87.60 91.80 131.94 126.45 30.20 36.37 Net Current Assets 5,243.20 4,157.13 6,158.14 5,262.50 4,610.61 2,487.27 1,824.78 1,472.43 1,154.77 784.61 Total Assets 10,421.61 9,541.08 8,773.18 7,834.14 6,496.06 4,086.04 3,522.59 2,928.34 2,473.75 2,086.31

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Shareholder's Funds 9,150.74 8,723.84 7,958.72 7,157.62 5,903.24 3,646.24 Share Capital 16.48 16.47 16.47 16.43 16.36 15.49 Total Reserves 9,134.21 8,705.99 7,940.59 7,127.95 5,861.46 3,614.26 Non-Current Liabilities 457.27 488.60 89.68 93.97 80.31 80.78 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 77.66 106.54 3.26 3.82 3.93 4.07 Long Term Provisions 145.99 137.21 0.00 0.00 0.00 0.00 Current Liabilities 1,564.85 1,398.36 729.13 582.02 512.53 359.02 Trade Payables 820.41 767.75 587.35 462.85 396.35 249.09 Other Current Liabilities 619.87 520.07 109.48 76.42 62.36 81.73 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 124.56 110.54 32.30 42.75 53.82 28.20 Total Liabilities 11,172.86 10,610.80 8,777.53 7,833.61 6,496.08 4,086.04 Net Block 4,147.23 3,946.75 1,570.55 1,502.19 954.23 968.10 Gross Block 5,613.37 5,011.68 2,294.95 2,081.32 1,430.70 1,347.81 Accumulated Depreciation 1,466.14 1,064.93 724.41 579.13 476.46 379.71 Non Current Assets 4,389.91 4,965.66 1,876.73 1,981.54 1,372.44 1,239.75 Capital Work in Progress 150.56 237.88 177.22 190.75 337.81 188.47 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 87.69 119.43 128.96 286.40 77.97 81.52 Other Non Current Assets 4.43 661.59 0.00 2.21 2.43 1.66 Current Assets 6,782.94 5,645.15 6,900.81 5,852.08 5,123.64 2,846.29 Current Investments 0.00 0.00 0.00 154.87 0.00 0.00 Inventories 1,685.22 1,655.24 1,945.30 1,185.67 1,275.17 756.28 Sundry Debtors 1,516.53 1,558.69 871.39 1,074.81 670.97 601.78 Cash & Bank 2,556.21 1,839.43 3,770.68 3,093.44 3,005.75 1,325.19 Other Current Assets 1,024.98 102.61 91.00 96.75 171.75 163.03 Short Term Loans & Adv. 875.13 489.19 222.44 246.55 87.60 91.80 Net Current Assets 5,218.09 4,246.79 6,171.68 5,270.05 4,611.11 2,487.27 Total Assets 11,172.85 10,610.81 8,777.54 7,833.62 6,496.08 4,086.04

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 1,073.67 1,135.97 367.89 791.29 604.93 700.93 185.06 201.93 476.46 224.09 PBT 1,465.59 1,405.50 1,048.40 1,619.04 1,334.85 992.87 686.36 501.56 578.01 459.11 Adjustment -5.15 23.15 37.38 -28.19 17.30 32.15 76.12 50.94 70.69 68.72 Changes in Working Capital -34.59 23.38 -407.00 -393.05 -435.80 -79.94 -353.94 -193.43 -10.86 -187.17 Cash after chg. in Working capital 1,425.84 1,452.02 678.78 1,197.80 916.36 945.07 408.53 359.07 637.85 340.66 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -352.17 -316.05 -310.89 -406.51 -311.43 -244.14 -223.47 -157.14 -161.39 -116.56 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 1,578.20 -2,923.92 1,208.22 -1,010.23 -1,524.55 -766.08 -314.14 -358.84 -96.65 -11.91 Net Fixed Assets -140.33 -227.74 -200.10 -503.56 -232.23 -193.54 -89.41 -86.66 55.65 -209.75 Net Investments -403.83 -2,377.58 154.87 -162.48 -0.55 0.00 0.00 0.00 0.17 0.00 Others 2,122.36 -318.60 1,253.45 -344.19 -1,291.77 -572.54 -224.73 -272.18 -152.47 197.84 Cash from Financing Activity -339.54 -7.40 14.92 34.90 1,238.46 -6.87 -2.93 -3.59 -116.42 -92.90 Net Cash Inflow / Outflow 2,312.33 -1,795.35 1,591.04 -184.04 318.84 -72.01 -132.01 -160.50 263.39 119.29 Opening Cash & Equivalents 116.20 1,905.22 311.18 491.92 169.50 236.40 372.84 533.08 273.23 157.81 Closing Cash & Equivalent 2,432.62 116.20 1,905.22 311.18 491.92 169.50 236.40 372.84 533.08 273.23

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Cash From Operating Activity 914.73 996.80 363.97 790.77 604.93 700.93 PBT 1,062.66 1,132.54 1,054.58 1,618.55 1,334.81 992.87 Adjustment 211.94 223.60 38.19 -28.27 17.30 32.15 Changes in Working Capital -6.06 -53.20 -417.94 -393.01 -435.76 -79.94 Cash after chg. in Working capital 1,268.53 1,302.95 674.83 1,197.28 916.35 945.07 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -353.80 -306.15 -310.87 -406.51 -311.43 -244.14 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 1,704.74 -1,756.91 1,208.19 -1,002.62 -1,524.00 -766.08 Net Fixed Assets -140.33 -227.74 -200.10 -503.56 -232.23 Net Investments -403.83 -2,377.58 154.87 -162.48 -0.55 Others 2,248.90 848.41 1,253.42 -336.58 -1,291.22 Cash from Financing Activity -433.48 -799.42 14.92 34.90 1,238.46 -6.87 Net Cash Inflow / Outflow 2,185.99 -1,559.53 1,587.08 -176.95 319.39 -72.01 Opening Cash & Equivalents 357.09 1,908.89 318.82 492.46 169.50 236.40 Closing Cash & Equivalent 2,556.21 357.09 1,908.89 318.82 492.46 169.50

Financial Ratios

Standalone /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 592.08 546.04 482.80 434.87 359.30 234.25 1847.12 1555.61 1348.70 1082.33 ROA 10.92% 11.39% 9.34% 16.92% 18.84% 20.32% 14.01% 11.89% 18.15% 16.31% ROE 11.62% 12.31% 10.28% 18.62% 20.97% 23.81% 17.14% 14.27% 21.97% 20.42% ROCE 15.87% 16.67% 13.97% 24.86% 28.00% 30.68% 26.11% 22.41% 30.04% 28.35% Fixed Asset Turnover 1.53 1.71 1.65 2.51 2.49 2.05 1.80 1.58 1.47 1.47 Receivable days 102.61 89.08 97.78 72.40 67.08 76.78 87.61 100.43 94.03 69.91 Inventory Days 111.48 140.38 158.00 102.05 107.06 115.61 127.19 100.26 91.25 92.53 Payable days 70.34 87.28 113.93 74.33 96.62 73.57 99.56 79.68 57.64 32.44 Cash Conversion Cycle 143.75 142.17 141.84 100.12 77.52 118.83 115.24 121.01 127.64 129.99 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 Interest Cover 65.18 180.20 142.41 309.98 392.34 139.24 193.80 122.59 91.43 28.97

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20
Book Value (Rs.) 555.40 529.56 483.12 434.84 359.30 234.25 ROA 6.41% 7.97% 9.40% 16.91% 18.84% 18.91% ROE 7.82% 9.26% 10.34% 18.61% 20.97% 21.29% ROCE 11.97% 13.63% 14.04% 24.85% 28.00% 27.39% Fixed Asset Turnover 1.06 1.55 1.66 2.51 2.49 1.95 Receivable days 99.92 78.29 97.99 72.40 67.08 83.41 Inventory Days 108.54 116.00 157.65 102.05 107.06 104.83 Payable days 138.65 113.80 113.72 74.35 96.63 52.71 Cash Conversion Cycle 69.81 80.48 141.92 100.10 77.51 135.53 Total Debt/Equity 0.03 0.04 0.00 0.00 0.00 0.00 Interest Cover 26.30 44.23 142.61 309.77 392.33 139.24

Top Investors:

hdfc mutual fund - hdfc mid-cap fund

mirae asset large & midcap fund

nippon life india trustee ltd-a/c nippon india growth fund

icici prudential india opportunities fund

sbi large & midcap fund

government pension fund global

uti-flexi cap fund

llp

Annual Reports:

News Update:

Gland Pharma reports 50% jump in Q1 consolidated net profit
5th Aug 2025, 17:45 PM

The total consolidated income of the company increased by 7.57% at Rs 1563.15 crore for Q1FY26
Read More
Gland Pharma gets GMP Compliance Certificate for Pashamylaram facility
14th Jul 2025, 10:12 AM

The company has received certificate of GMP for aseptically prepared Powder for injection, infusion and inhalation
Read More
Gland Pharma gets EIR from USFDA for Visakhapatnam facility
24th Jun 2025, 12:00 PM

The said inspection was conducted between February 19, 2025 and February 25, 2025
Read More
Gland Pharma’s subsidiary gets 11 observations for Fontenay manufacturing facility
5th Jun 2025, 10:22 AM

There will be no disruption in the manufacturing operations due to this final inspection report
Read More
Gland Pharma gets USFDA’s approval for Angiotensin II Acetate Injection
4th Jun 2025, 09:12 AM

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA of La Jolla Pharma LLC
Read More

Gland Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543245 | NSE: GLAND

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Gland Pharma Ltd.

Pharmaceuticals & Drugs

BSE: 543245 | NSE: GLAND

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: